EASD 2023
/
The EASD Annual Meeting is one of the largest scientific congresses, presenting the latest results from basic and clinical diabetes research. The 569th EASD Annual Meeting takes place in Hamburg 2-6 October 2023.
Presentations from members of Oslo Diabetes Research Center at EASD 2023:
Presentations:
1. Country background, education level, employment and disability in young-onset type 2 diabetes
K. Tibballs, L. Kirkebøen, A. Jenum, J. Straand, E.S. Buhl;
2. Remission of type 2 diabetes 5 years after gastric bypass versus sleeve gastrectomy: the Oseberg RCT
J.W. Hauge, H. Borgeraas, J.K. Hertel, M.C. Småstuen, R. Sandbu, L.K. Johnson, M. Svanevik, K.I. Birkeland, R.L. Kolotkin, T.G. Valderhaug, H.L. Gulseth, J. Hjelmesæth, D. Hofsø;
3. Lower NT-proBNP and higher cardiovascular risk factors in south Asian vs Nordic women 1-3 years after gestational diabetes
A. Sharma, I. Nermoen, S. Lee-Ødegaard, E. Qvigstad, H.L. Gulseth, S.T. Sollid, K.I. Birkeland, P.L. Myhre1;
4. Prediabetes and diabetes 11 years after pregnancy in ethnic minority groups with and without gestational diabetes
C. Waage, I. Mdala, A. Brænd, A.K. Jenum, K.I. Birkeland;
5. Methylation risk score for gestational diabetes on DNA methylation patterns associated with type 2 diabetes
T. Linares-Pineda, N. Fragoso Bargas, M. Picón, M. Molina-Vega, A.K. Jenum, L. Sletner, S. Lee-Ødegård, J.O. Opsahl, G.-H. Moen, E. Qvigstad, R.B. Prasad, K.I. Birkeland, S. Morcillo, C. Sommer;
6. Replication of interaction between PTPN22 susceptibility variants and caesarean section in type 1 diabetes risk: the Norwegian mother, father and child cohort study
L. Stene, K. Størdal, T. Skrivarhaug, G. Tapia;
7. Residual insulin after anti-viral treatment with pleconaril and ribavirin in new onset type 1 diabetes: a randomised, placebo-controlled, double blind, clinical trial
I. Mynarek, L. Krogvold, E. Ponzi, F.C.B. Mörch, T.W. Hessel, T. Roald, N. Lindblom, J. Westman, P. Barker, J. Ludvigsson, K.F. Hanssen, H. Hyöty, J. Johannesen, K. Dahl-Jørgensen;
8. Adipose tissue insulin resistance, liver fat and fetuin-A in South Asian and Nordic women after gestational diabetes
S. Lee-Ødegård, A. Suntharalingam, H.L. Gulseth, I. Nermoen, S.T. Sollid, E. Qvigstad, K.I. Birkeland, A. Sharma;
9. Trends in drugs for diabetes and obesity 2004-2021 in Norway
· P.L. Ruiz, K. Nøkleby, Ø. Karlstad, H.L. Gulseth, K. Sveen, E. Qvigstad, K. Furu, Norway
10. Prediction of mortality and validation of the ATC-code based Rx-risk comorbidity index in the “Outcomes & Multi-Morbidity In Type 2 diabetes” (OMIT) cohort
· E.S. Buhl, J. Igland, R. Forster, A. Jenum, R.B. Strandberg, T.J. Berg, J. Røssberg, M.M. Iversen, Norway
Chairs:
DSO 40 Metabolism in humans
Chair: K. I. Birkeland;
Dept. of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
S 27 The evolving enigma of type 1 diabetes
Chair: L. C. Stene;
Department of Chronic Diseases and Ageing, Norwegian Inst. of Public Health, Oslo, Norway.
SO 02 Lifestyle matters